VYGR Stock VYGR is expected to report earnings to fall -135% to -44 cents per share on May 13

A.I.dvisor
at Tickeron.com
05/12/24
Loading...
VYGR - Voyager Therapeutics
Voyager Therapeutics Earnings Graph
Q1'24
Est.
$-0.44
Q4'23
Beat
by $1.54
Q3'23
Missed
by $0.01
Q2'23
Beat
by $0.06
Q1'23
Beat
by $2.87
The last earnings report on December 31 showed earnings per share of $1.25, beating the estimate of -29 cents. P/B Ratio (1.943) is normal, around the industry mean (10.609). P/E Ratio (2.842) is within average values for comparable stocks, (160.883). VYGR's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.422). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (1.505) is also within normal values, averaging (236.959). With 388.86K shares outstanding, the current market capitalization sits at 459.04M.
View a ticker or compare two or three
VYGRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of gene therapies for fatal and debilitating diseases of the central nervous system

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
75 Hayden Avenue
Phone
+1 857 259-5340
Employees
162
Web
https://www.voyagertherapeutics.com